EVIDENCE LIBRARY
How Is Methylone Pharmacokinetics Different From MDMA? Controlled Human Dosing Evidence
Controlled dosing in 12 volunteers found approximately dose-proportional methylone exposure from 50 to 200 mg, unlike MDMA’s previously described nonlinear pharmacokinetics.
Methylone is a synthetic cathinone sometimes sold as, or found with, MDMA. The two compounds are structurally related, but a controlled human study found an important pharmacokinetic difference: methylone exposure increased approximately in proportion to dose across the tested range, while MDMA is known for nonlinear pharmacokinetics.
What did the study do?
Twelve healthy male volunteers participated in a randomized, double-blind, placebo-controlled crossover study. Oral methylone doses ranged from 50 to 200 mg. Investigators collected 468 plasma samples and validated an LC-MS/MS method for methylone, MDMA, and their metabolites.
The design allowed the researchers to follow the concentration–time curve rather than infer it from a single forensic specimen.
How quickly did methylone reach its peak?
Methylone was absorbed rapidly. Median time to maximum concentration was about 1.5 hours after 50 mg and approximately two hours after the higher doses. Reported peak concentrations were:
- 153 ng/mL after 50 mg;
- 304 ng/mL after 100 mg;
- 355 ng/mL after 150 mg; and
- 604 ng/mL after 200 mg.
Estimated half-lives ranged from 5.8 to 6.9 hours. Concentrations remained measurable 24 hours after administration, with the later values increasing as dose increased.
What does “linear pharmacokinetics” mean here?
Across 50–200 mg, methylone’s maximum concentration and area under the concentration–time curve increased in a roughly dose-proportional manner. MDMA can behave differently because it inhibits CYP2D6, a pathway involved in its own metabolism. As MDMA dose rises, exposure may increase more than simple proportional scaling predicts.
Linear does not mean identical across people. Absorption, body composition, metabolism, specimen timing, health, co-administered drugs, and analytical variation still contribute to individual differences.
What about the metabolite HMMC?
HMMC reached lower concentrations and had lower total exposure than methylone. Its Cmax was approximately 10–14 times lower, and its 24-hour area under the curve was approximately 21–29 times lower. Parent-to-metabolite patterns can help describe exposure, but they do not create a universal clock for every case.
Was the analytical method validated?
The LC-MS/MS method used matrix-matched validation consistent with OSAC guidance. Calibration coefficients were at least 0.99, no carryover was observed, and within- and between-run coefficients of variation were below 20%. The authors evaluated bias, recovery, matrix effects, dilution integrity, and stability.
What can a forensic toxicologist conclude?
The study offers controlled reference data for plasma after known oral doses. It does not justify converting an unknown case concentration into an exact dose. The dose groups were small—only three to seven participants contributed to individual methylone dose conditions—and all participants were men. Street products may also contain both methylone and MDMA, other cathinones, or unrelated adulterants.
A defensible interpretation should distinguish:
- identification of methylone from MDMA;
- the concentration and specimen type;
- time between use and collection;
- co-detected substances; and
- whether the question concerns exposure, timing, toxicity, or impairment.
The paper’s strongest contribution is not a concentration cutoff. It is evidence that methylone and MDMA should not be assumed to share the same dose–concentration behavior merely because they are chemically related and may appear in the same market.
Source
Poyatos L, et al. “Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans.” International Journal of Molecular Sciences (2022). PMID 36498963. PubMed | Full text | DOI: 10.3390/ijms232314636.